伊立替康联合靶向药物在晚期结直肠癌治疗中的应用  

Use of irinotecan plus targeted drugs for the treatment of advanced colorectal cancer

作　　者：郑宇[1] 潘宏铭[1] 

机构地区：[1]浙江大学医学院附属邵逸夫医院肿瘤内科,杭州310016

出　　处：《临床药物治疗杂志》2012年第3期52-57,共6页Clinical Medication Journal

摘　　要：伊立替康是转移性结直肠癌的主要治疗药物,本文阐述了伊立替康在多项Ⅱ期、Ⅲ期临床研究中的研究结果,表明伊立替康与西妥昔单抗、贝伐珠单抗、帕尼单抗等靶向药物联合在一线、二线、多重耐药转移性结直肠癌治疗中有较好的疗效。但伊立替康与酪氨酸激酶抑制药、舒尼替尼等小分子靶向药物联合疗效不佳。而具体的药物的分子生物学机制与临床疗效及毒副反应的关系,尚需进一步研究。Irinotecan is an important chemotherapy medicine for the treatment of metastatic colorectal cancer. This article reviewed the results of irinotecan in phase II, 111 clinical trials, which had been demonstrated the benefit of irinotican treatment when in combination with cetuximab, bevacizumab, panitumumab in first line to heavily pretreated colorectal cancer. However, poor results has been found in some trials when irinotecan in combination with the tyrosine kinase inhibitors, sunitinib and other small molecules. So, the relationship between the mechanism of molecular biology, clinical efficacy and drug toxicity of such treatment need to be further investigated.

关 键 词：伊立替康 西妥昔单抗 贝伐珠单抗 帕尼单抗 酪氨酸激酶抑制药 舒尼替尼 

分 类 号：R453[医药卫生—治疗学] R735.3[医药卫生—临床医学]